“We are very pleased to have completed this factory upgrade,” Stein Ulve, CEO and founder of Eevia Health Oy. “It puts us as a competitive company for high quality, branded ingredients in a 500 billion euro global nutraceutical ingredients market. The investments will especially benefit our manufacturing of polyphenolic extracts from arctic bilberries and lingonberries, as well as elderberries. Some of the improvements are radical. For instance, earlier, the residence time for extraction liquids [the time extracted liquid has to be in the process step] was four hours, while now this step only takes a few seconds. This greatly benefits quality.”
Eevia Health Oy will celebrate the reopening of its production facility in Kauhajoki, Finland, with a formal opening ceremony as a live-streamed webinar at the end of June.
The company, founded in March 2017, specializes in ingredients with high concentrations of bioactive compounds extracted from plants in the Finnish forests above the Arctic Circle. Its focus is on prophylactic health benefits, meaning that their ingredients are intended to reduce the risk of certain diseases, including products studied for their ability to modulate immune function through effects on the Th1-type cytokines. Similarly, Eevia Health is developing a product observed to inhibit protein accumulation in the RPE-cells in the retina, which researchers believe may reduce the risk of developing age-related macular degeneration.
Eevia is a small, but fast-growing manufacturer of 100% organic certified plant extracts, and all of its raw materials, including lingonberry, bilberry, Chaga mushroom, and pine bark, are hand-picked in a sustainable fashion. Its extracts are available globally as ingredients for dietary supplements and foods.